Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imbruvica
Pharma
Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial
In an industry first, Lilly found that adding Jaypirca to a fixed-duration regimen of venetoclax and rituximab significantly extended PFS.
Angus Liu
Apr 13, 2026 10:16am
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Dec 9, 2025 7:30am
AbbVie, BeOne end BTK inhibitor patent fight
Oct 2, 2025 10:29am
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
Lilly's BTK Jaypirca makes the grade versus Imbruvica
Jul 29, 2025 4:56pm
